BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
01 nov. 2018 16h10 HE
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29 oct. 2018 08h30 HE
|
BioDelivery Sciences International, Inc.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 ...
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
23 oct. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
25 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
13 sept. 2018 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
10 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living...
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
21 août 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
15 août 2018 09h26 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09 août 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
30 juil. 2018 07h55 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...